🚨 #APHINITY Trial • #ESMOBreast25🚨 Pertuzumab (Perjeta) + trastuzumab (Herceptin) + chemo significantly improves long-term survival for people with HER2-positive early-stage breast cancer, especially those with lymph node involvement or hormone receptor–positive tumors. Read more 🔗 bit.ly/ESMO2025
Final Overall Survival Results from the APHINITY Trial Confirm Long-Term Benefit of Adjuvant Pertuzumab in Early HER2-Positive Breast Cancer
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #OS #APHINITY #Pertuzumab #BreastCancer #HER2
completely ignoring the industry standard of care & clinical guidelines, probably because it's very expensive & so it's not good for bottom line profits.
#MedicareForAll #Medicare4All #healthinsurance #insurancedenial #perjeta #BreastCancer #HealthcareJustice #PatientAdvocacy #aphinity #healthcare
